10-Jun-2021 | Facts and Factors
The latest report published by facts and factors titled “irritable bowel syndrome (IBS) diagnostics market” has a global perspective on the latter coupled with the market size, volume, drivers, and restraints to name a few. We estimate that the global irritable bowel syndrome (IBS) diagnostics market will hold a value of USD 2.3 Billion with a CAGR growth of 9.7% which was previously subjected at USD 1.2 Billion in the year 2020.
Irritable bowel syndrome is a medical condition that pertains to irregular bowel movement and is accompanied by extreme pain in the stomach followed by diarrhoea, cramping, and constipation among others. IBS is a fairly simple diagnosis that can be detected by a range of laboratory tests and imaging tests with a wider range of medication as treatment measures. The driving factors behind the growth of the irritable bowel syndrome (IBS) diagnostics market are a rise of prevalence of factors such as food allergies, predominant development of gastroenteritis, sporadic movements of colon, irregular composition of serotonin in the colon, and a rise in celiac diseases, among others.
Additional factors include improvement in testing methods and extensive research and developmental means for improved accuracy and less down time during testing. Moreover, the approval of linzess among regions of U.S, Europe, and Asia-Pacific is expected to propel the growth of IBS diagnostic market over the forecast period. Increased awareness among consumers and a widened spending power coupled with established healthcare facilities will further lead the market toward a positive outlook.
Top Key Market Players
The key participants in the irritable bowel syndrome (IBS) diagnostics market are Synergy Pharmaceuticals, Banusch Health, Synthetic Biologics, Inc., Ardelyx, Johnson & Johnson, and Novartis AG, among others.
Report Attribute |
Details |
Market Size in 2020 |
USD 1.2 Billion |
Projected Market Size in 2026 |
USD 2.3 Billion |
CAGR Growth Rate |
9.7% CAGR |
Base Year |
2020 |
Forecast Years |
2021-2026 |
Key Market Players |
Allergan, Astellas Pharma, Inc., Takeda Pharmaceuticals Company Limited, AstraZeneca, Sebela Pharmaceuticals, Inc., Synergy Pharmaceuticals, Banusch Health, Synthetic Biologics, Inc., Ardelyx, Johnson & Johnson, and Novartis AG, among others |
Key Segment |
By Type, By Product, By Distribution Channel, and By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Market Dynamics
The market is highly unmeasured and is often accompanied by product launches, mergers & acquisitions, and constant developmental cycles among the key players in order to stay competitive. Here are a few noted developments –
- Commonwealth Diagnostics International (CDI), Inc. recently announced the launch of commercially based validated biomarkers for diarrhoea predominated and mixed-typed irritable bowel syndrome (IBS-D, IBS-M) for home-testing solutions.
- Gemelli Biotech recently collaborated with Advanced Medical German Co. in order to enter a previously untapped region to distribute their proprietary blood testing kits for IBS – ibs-smart.
On the basis of type, the global irritable bowel syndrome (IBS) diagnostics market can be divided into ISB-C, ISB-D, and Mixed IBS on the bases of type. The IBS-C can be further broken down into linzess/constella, amitiza, and others and the IBS-D can be broken down into xifaxan, viberzi, and others. The IBS-C segment is expected to dominate owing to various contributing factors such as a surge of uptake of drugs such as linzess/constella & amitiza.
On the basis of product, the global irritable bowel syndrome (IBS) diagnostics market can be broken down into rifaximin, eluxadoline, Lubiprostone, linaclotide, and others. The segment pertaining to rifaximin will account for the largest marker share during the advent of the forecast owing to factors such as rise in geriatric population, increased consumer spending, reliable diagnosis, and advancements in technology.
North America Will Lead The Market Over The Forecast In Terms Of Revenue
North America is expected to recoup the largest market share during the forecast in terms of global revenue collection followed by the Europe and Asia-Pacific. The market growth in North America is primarily due to the well-established healthcare facilities, government incentives, and presence of key players in the region. Moreover, rising patient awareness and increased consumer spending power for diagnostics tests will propel the growth of the irritable bowel syndrome (IBS) diagnostics market during the forecast period.
Browse the full “Irritable Bowel Syndrome (IBS) Diagnostics Market By Type (IBS-C, IBS-D, and Mixed IBS), By Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, & Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies & Online Pharmacies), And By Regions – Global & Regional Industry Perspective, Comprehensive Analysis, and Forecast, 2021 – 2026” report at https://www.fnfresearch.com/irritable-bowel-syndrome-diagnostics-market
The global irritable bowel syndrome (IBS) diagnostics market can be segmented into:
Global Irritable Bowel Syndrome (IBS) Diagnostics Market: By Type Segment Analysis
- ISB-C
- Linzess/Constella
- Amitiza
- Others
- ISB-D
Global Irritable Bowel Syndrome (IBS) Diagnostics Market: By Product Segment Analysis
- Rifaximin
- Eluxadoline
- Lubiprostone
- Linaclotide
- Others
Global Irritable Bowel Syndrome (IBS) Diagnostics Market: By Distribution Channel Segment Analysis
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
Global Irritable Bowel Syndrome (IBS) Diagnostics Market: By Regional Segment Analysis
- North America
- Europe
- UK
- France
- Germany
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of MEA
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
